Gabapentinoid Polypharmacy Among Medicare Beneficiaries During the Poststroke Recovery Period
- 20 May 2026
- journal article
- Published by Wiley in Health Services Research
- Vol. 61 (3) , e70133
Abstract
Objective: To describe patterns of gabapentinoid (Gabapentin and Pregabalin) use and concurrent use with other central nervous system (CNS) acting pain medications (opioids and benzodiazepines) among US Medicare beneficiaries following acute ischemic stroke (AIS). Study Setting and Design: We analyzed new outpatient gabapentinoid prescriptions in older stroke survivors between 2009 and 2022. We calculated the percent of new gabapentinoid initiators within 6 months of stroke discharge and analyzed concurrent pain medications prescribed within 30 days of gabapentinoid initiation. We presented trends and geographic patterns standardized by age, discharge destination, and modified Rankin Scale (mRS) to control for variations in the sample composition by age and stroke severity over time. Data Sources and Analytic Sample: We analyzed a 20% sample of US Medicare beneficiaries aged 65 years or older who were hospitalized for AIS. We included those who met Medicare enrollment criteria, had no prior stroke, no prior gabapentinoid use within 6 months, and were discharged home within 30 days of hospitalization. Principal Findings: Among 153,728 stroke survivors, 4.9% received new gabapentinoid prescriptions within 6 months postdischarge. Of the 7595 gabapentinoid initiators, 1579 (21%) had concurrent opioid and 653 (8.6%) had concurrent benzodiazepine prescriptions. In the sample, the median age was 78 years (Quartile Range: 72–84), 55% were female, and 81% were non‐Hispanic White. The standardized percentage of gabapentinoid initiators increased from 3.8% in 2009 to 5.9% in 2022 (crude: 3.6% in 2009 to 5.8% in 2022). Despite increases in the number of gabapentinoid initiators, the percentage of concurrent opioid users remained low over time, around 1% of the study population. We observed variation in gabapentinoid initiation and concurrent use with opioids by geography. Conclusions: From 2009 to 2022, poststroke gabapentinoid use increased in older adults, but concurrent use with opioids remained low over time.Keywords
Funding Information
- National Institutes of Health (R01AG073410‐01)
- National Institutes of Health (K24DA061696‐01)
This publication has 29 references indexed in Scilit:
- Experiences of misuse and symptoms of dependence among people who use gabapentinoids: A qualitative systematic reviewInternational Journal of Drug Policy, 2024
- Gabapentinoid prescribing patterns and predictors utilizing neural networks: An analysis across emergency departments Nationwide between 2012 and 2021The American Journal of Emergency Medicine, 2024
- Concurrent Gabapentin and Opioid Use and Risk of Mortality in Medicare Recipients with Non‐Cancer PainClinical Pharmacology & Therapeutics, 2023
- Trends in the Use of Gabapentinoids and Opioids in the Postoperative Period Among Older AdultsJAMA Network Open, 2023
- Concurrent Use of Prescription Opioids and Gabapentinoids in Older AdultsAmerican Journal of Preventive Medicine, 2021
- Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare BeneficiariesValue in Health, 2021
- A Clinical Overview of Off-label Use of Gabapentinoid DrugsJAMA Internal Medicine, 2019
- Gabapentinoid Use in the United States 2002 Through 2015JAMA Internal Medicine, 2018
- Prevalence and Time Course of Post-Stroke Pain: A Multicenter Prospective Hospital-Based StudyPain Medicine, 2015
- Safety and efficacy of pregabalin in patients with central post-stroke painPain, 2011